BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Its products in clinical development include Kyndrisa, Pegvaliase, Reveglucosidase alfa, Vosoritide (formerly BMN 111), Cerliponase alfa, BMN 044, BMN 045, BMN 053 and BMN 270. Vimizim is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type IV (MPS IV A). Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) indicated for patients with mucopolysaccharidosis VI (MPS VI). Kuvan is a synthetic oral form of 6R-BH4 indicated for patients with phenylketonuria (PKU).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BMRN
  • CUSIP: 09061G10
Key Metrics:
  • Previous Close: $94.97
  • 50 Day Moving Average: $94.37
  • 200 Day Moving Average: $86.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -82.95
  • P/E Growth: -0.96
  • Market Cap: $15.73B
  • Outstanding Shares: 163,465,000
  • Beta: 1.12
Additional Links:
Companies Related to BioMarin Pharmaceutical:

Analyst Ratings

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (?)
Ratings Breakdown: 2 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $122.24 (27.04% upside)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateFirmActionRatingPrice TargetDetails
8/19/2016Piper Jaffray Cos.Reiterated RatingOverweightView Rating Details
8/17/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/8/2016Credit Suisse Group AGSet Price TargetBuy$111.00View Rating Details
8/5/2016JPMorgan Chase & Co.Boost Price TargetOverweight$120.00 -> $127.00View Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$107.00 -> $113.00View Rating Details
8/5/2016Barclays PLCBoost Price TargetOverweight$105.00 -> $125.00View Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00View Rating Details
7/28/2016WedbushReiterated RatingNeutral$108.00View Rating Details
7/28/2016Cowen and CompanyReiterated RatingBuyView Rating Details
7/28/2016Leerink SwannReiterated RatingOutperform$107.00View Rating Details
7/28/2016Robert W. BairdBoost Price TargetOutperform$110.00 -> $115.00View Rating Details
6/20/2016Oppenheimer Holdings Inc.Reiterated RatingMarket Perform$99.00View Rating Details
6/1/2016Goldman Sachs Group Inc.Reiterated RatingBuy$126.00View Rating Details
5/31/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
4/7/2016BMO Capital MarketsInitiated CoverageOutperform$99.00View Rating Details
1/15/2016Bank of America Corp.Reiterated RatingBuy$165.00 -> $135.00View Rating Details
10/13/2015Raymond James Financial Inc.Reiterated RatingOutperform$157.00View Rating Details
8/6/2015Deutsche Bank AGReiterated RatingBuy$160.00View Rating Details
8/4/2015NomuraReiterated RatingBuy$163.00 -> $173.00View Rating Details
8/4/2015SunTrust Banks Inc.Reiterated RatingBuyView Rating Details
6/18/2015Canaccord GenuityBoost Price TargetBuy$115.00 -> $150.00View Rating Details
2/26/2015Brean CapitalReiterated RatingHoldView Rating Details
2/26/2015Citigroup Inc.Reiterated RatingBuy$94.00 -> $133.00View Rating Details
1/29/2015Evercore ISIInitiated CoverageBuyView Rating Details
11/3/2014Wells Fargo & Co.UpgradeMarket Perform -> OutperformView Rating Details
(Data available from 8/28/2014 forward)


Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.51)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.43)$201.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.47)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.41)($0.23)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014($0.44)($0.01)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
Current Year EPS Consensus Estimate: $-0.28 EPS
Next Year EPS Consensus Estimate: $-1.16 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($2.51)($0.40)($0.94)
Q2 20166($4.02)($0.27)($2.11)
Q3 20166($0.63)($0.24)($0.46)
Q4 20165($0.67)($0.26)($0.53)
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.28)($0.28)($0.28)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.00View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.00View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.00View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.00View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.00View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.00View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for BioMarin Pharmaceutical (NASDAQ:BMRN)
News IconStocks Buzz: Kimberly Clark Corp (NYSE:KMB), BioMarin Pharmaceutical Inc.(NASDAQ:BMRN) - NYSE Journal (press release) (NASDAQ:BMRN) - August 26 at 3:50 PM
News IconBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from Biotechnology – Todays Top Gains (NASDAQ:BMRN) - August 25 at 8:46 AM logoForbes Ranks BioMarin 10th Most Innovative Company in the World (NASDAQ:BMRN) - August 24 at 12:08 PM logo[$$] Smaller Biotech Buyout Targets After Medivation (NASDAQ:BMRN) - August 24 at 12:08 PM
News IconInvestor's Alert: BioMarin Pharmaceutical Inc.(NASDAQ:BMRN), Incyte Corporation(NASDAQ:INCY) - NYSE Journal (press release) (NASDAQ:BMRN) - August 23 at 3:57 PM
News Icon2 Biotech Stocks News And Price Trends: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), ProNAi Therapeutics, Inc ... - The Voice Registrar (NASDAQ:BMRN) - August 23 at 3:57 PM logoBioMarin Pharmaceutical Inc., TESARO Inc Options Volume Soars ... - Schaeffers Research (blog) (NASDAQ:BMRN) - August 23 at 8:03 AM
News IconBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Overweight Rating ... - BNB Daily (blog) (NASDAQ:BMRN) - August 23 at 8:03 AM logoWhy Syngenta, Valeant Pharmaceuticals, and BioMarin Pharmaceutical Jumped Today (NASDAQ:BMRN) - August 22 at 7:19 PM logoNotable Monday Option Activity: CELG, BMRN, VIA (NASDAQ:BMRN) - August 22 at 3:58 PM logoBioMarin Pharmaceutical Inc., TESARO Inc Options Volume Soars on Sector Tailwinds (NASDAQ:BMRN) - August 22 at 3:58 PM logoBetting on BioMarin (NASDAQ:BMRN) - August 22 at 3:57 PM
News IconBiotechnology: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position of the day (NASDAQ:BMRN) - August 20 at 8:51 AM
News IconBiotechnology: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position of the day - Twin County News (NASDAQ:BMRN) - August 19 at 4:33 PM logoBreak Up Gilead Sciences? Not So Fast (NASDAQ:BMRN) - August 19 at 12:14 PM logoBioMarin Pharma (BMRN): Executing Well But For How Long - Piper Jaffray (NASDAQ:BMRN) - August 18 at 12:18 PM
News IconTop Gainers of the Day: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from Biotechnology (NASDAQ:BMRN) - August 16 at 9:07 PM logoWhy You Shouldn't Bet Against BioMarin Pharmaceutical (BMRN) Stock (NASDAQ:BMRN) - August 16 at 12:35 PM
News IconIntraday Active Biotech Stocks News: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Amgen Inc. (NASDAQ:AMGN) - The Voice Registrar (NASDAQ:BMRN) - August 15 at 4:00 PM
News IconToday's Top Gainers in the Market BioMarin Pharmaceutical Inc ... - The Daily Leicester (NASDAQ:BMRN) - August 13 at 11:19 AM
News IconIs BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a large market cap stock a smart buy? (NASDAQ:BMRN) - August 11 at 3:57 PM logoBIOMARIN PHARMACEUTICAL INC Financials (NASDAQ:BMRN) - August 11 at 3:57 PM logoStocks In Queue: ConAgra Foods, Inc. (CAG), BioMarin Pharmaceutical Inc. (BMRN), PDL BioPharma, Inc. (PDLI) - iStreetWire (NASDAQ:BMRN) - August 11 at 12:02 PM logoInvestors Snatch BMRN 5.6% Cheaper Than Its Secondary Stock Offering (NASDAQ:BMRN) - August 11 at 10:40 AM logoSolid BioMarin Pharmaceutical Inc. Earnings, More to Come (NASDAQ:BMRN) - August 10 at 9:21 PM logoWhy Wayfair Inc (W), BioMarin Pharmaceutical Inc. (BMRN) and Norwegian Cruise Line Holdings Ltd (NCLH) Are 3 of Today’s Worst Stocks (NASDAQ:BMRN) - August 9 at 5:37 PM logoETF’s with exposure to BioMarin Pharmaceutical, Inc. : August 9, 2016 (NASDAQ:BMRN) - August 9 at 5:00 PM logoThere Have Been 20 Secondary Offerings Over The Last 2 Days (NASDAQ:BMRN) - August 9 at 3:28 PM logoBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Brokerage Rating Update - Investor Newswire (NASDAQ:BMRN) - August 9 at 12:48 PM logoBioMarin Announces Pricing of Public Offering of Common Stock (NASDAQ:BMRN) - August 9 at 12:48 PM
News IconHC Stocks in Focus: Skyline Medical Inc (NASDAQ:SKLN), BioMarin ... - share market updates (press release) (NASDAQ:BMRN) - August 8 at 9:19 PM logo4:36 pm BioMarin Pharm commences 7.5 mln common stock offering (NASDAQ:BMRN) - August 8 at 9:19 PM logoBioMarin Announces Public Offering of Common Stock (NASDAQ:BMRN) - August 8 at 9:19 PM logoBioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering (NASDAQ:BMRN) - August 8 at 9:19 PM logoTake a look at Analyst Tips: Mylan N.V. (NASDAQ:MYL) , BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Street Updates (NASDAQ:BMRN) - August 8 at 3:55 PM logoBIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits (NASDAQ:BMRN) - August 8 at 3:55 PM logoBIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report (NASDAQ:BMRN) - August 8 at 3:55 PM logoBioMarin Pharmaceutical, Inc. :BMRN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:BMRN) - August 8 at 3:55 PM logoWhy BioMarin Pharmaceutical Inc. Stock Rose 22.2% in July (NASDAQ:BMRN) - August 6 at 11:36 PM
News IconLeading stocks in today’s market: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) (NASDAQ:BMRN) - August 5 at 9:17 PM
News IconStock Attracting Analyst Attention: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - The Voice Registrar (NASDAQ:BMRN) - August 5 at 3:55 PM
News IconAnalyst Research Roundup: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Mondelez International, Inc. (NASDAQ ... - TWN (NASDAQ:BMRN) - August 5 at 3:55 PM logoJefferies Raises Price Target on BioMarin Pharma (BMRN) to $120; Reiterates Buy (NASDAQ:BMRN) - August 5 at 12:17 PM logoA Look At The Upcoming BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) BLA (NASDAQ:BMRN) - August 5 at 12:17 PM logoEdited Transcript of BMRN earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:BMRN) - August 5 at 12:17 PM logoBioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped (NASDAQ:BMRN) - August 5 at 12:17 PM logoBioMarin Pharmaceutical Inc.: BioMarin Announces Second Quarter 2016 Financial Results (NASDAQ:BMRN) - August 4 at 9:38 PM logoEARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q2 Earnings Report (NASDAQ:BMRN) - August 4 at 9:38 PM logoBioMarin reports 2Q loss (NASDAQ:BMRN) - August 4 at 9:38 PM
News IconUpdate on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for the day (NASDAQ:BMRN) - August 4 at 4:00 PM


BioMarin Pharmaceutical (NASDAQ:BMRN) Chart for Sunday, August, 28, 2016

Last Updated on 8/28/2016 by Staff